03.01.10
Oral intake of Peptan, from Rousselot, may have a positive impact on osteoporosis. Researchers conducted an in vivo study on ovariectomized mice, used to simulate postmenopausal osteoporosis, which leads to a lower bone mineral density (BMD).
Animals were divided into three groups: a control group (non ovariectomized), a group of ovariectomized mice, both fed with a normal diet, and a group of ovariectomized mice that received a diet containing Peptan. After 12 weeks, the BMD of the group fed with Peptan was higher. Confirmation of Peptan benefits on bone health was obtained by the measures of Carboxy Terminal Telopeptide (CTX), a usual marker of bone resorption. CTX was significantly lower in mice fed with Peptan indicating that bone resorption was reduced.
Researchers concluded that Peptan may restore bone density in simulated post-menopausal osteoporosis by stimulating osteoblast growth and differentiation. For further information: www.rousselot.com
Animals were divided into three groups: a control group (non ovariectomized), a group of ovariectomized mice, both fed with a normal diet, and a group of ovariectomized mice that received a diet containing Peptan. After 12 weeks, the BMD of the group fed with Peptan was higher. Confirmation of Peptan benefits on bone health was obtained by the measures of Carboxy Terminal Telopeptide (CTX), a usual marker of bone resorption. CTX was significantly lower in mice fed with Peptan indicating that bone resorption was reduced.
Researchers concluded that Peptan may restore bone density in simulated post-menopausal osteoporosis by stimulating osteoblast growth and differentiation. For further information: www.rousselot.com